{"id":390162,"date":"2020-09-17T00:00:00","date_gmt":"2020-09-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0013-2020-biopharma-platinum-sensitive-ovarian-cancer-spotlight-on-unmet-need\/"},"modified":"2026-04-28T11:23:34","modified_gmt":"2026-04-28T11:23:34","slug":"unneon0013-2020-biopharma-platinum-sensitive-ovarian-cancer-spotlight-on-unmet-need","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0013-2020-biopharma-platinum-sensitive-ovarian-cancer-spotlight-on-unmet-need\/","title":{"rendered":"Platinum-Sensitive Ovarian Cancer Spotlight on Unmet Need"},"content":{"rendered":"<p>The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca\u2019s Lynparza, GSK\u2019s Zejula, and Clovis Oncology\u2019s Rubraca, have revolutionized the therapeutic landscape of platinum-sensitive ovarian cancer, where platinum-based regimens used to be the standard of care. Although substantial improvements have been made with the FDA\u2019s 2019 approval of Lynparza for first-line maintenance therapy in advanced ovarian cancer, opportunity exists to develop more effective therapies for platinum-sensitive disease, while optimal sequencing of these therapies remains an unmet need.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals in surveyed medical oncologists\u2019 prescribing decisions? What are the hidden opportunities that developers could leverage?<\/li>\n<li>How do current therapies, such as the PARP inhibitors, perform on key clinical attributes for this patient population?<\/li>\n<li>What are the greatest areas of unmet need and most attractive opportunities for platinum-sensitive ovarian cancer?<\/li>\n<li>What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 62 U.S. and 30 European medical oncologists\u00a0fielded in June 2020<\/p>\n<p><strong>Key companies:<\/strong>\u00a0 AstraZeneca, GSK, Clovis Oncology<\/p>\n<p><strong>Key drugs:<\/strong> Lynparza, Zejula, Rubraca<\/p>\n","protected":false},"template":"","class_list":["post-390162","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-product-unmet-need","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390162\/revisions"}],"predecessor-version":[{"id":393287,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390162\/revisions\/393287"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}